Visceral adiposity and oesophageal adenocarcinoma : exploring the role of the insulin like-growth factor axis

Abstract

In the modem era there is a consistent reported trend of markedly improved operative and oncologic outcomes from high-volume oesophageal programmes within academic medical centres. The current benchmark survival rate in patients treated with curative intent is between 35 to 50%, but this does not account for the majority of patients who have advanced disease and are unsuitable for treatment with curative intent. Clearly, new treatment strategies are warranted.